You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Bioactive Prosthetic Vascular Graft
SBC: BIOSURFACES INC Topic: NHLBIDESCRIPTION (provided by applicant): Over 60,000 prosthetic grafts, which are primarily comprised of polyethylene terephthalate (polyester) or expanded polytetrafluoroethylene (ePTFE), are implanted in the United States each year. Unfortunately, these grafts continue to have high failure rates due to secondary complications associated with acute thromboses and incomplete, unregulated cellular prol ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
ACES: A Product to Suppress or Enhance Critical Components in Acoustic Signals
SBC: Speech Technology and Applied Research Corporation Topic: NIDCDDESCRIPTION (provided by applicant): Common acoustic environments are often complex mixtures of sounds from multiple acoustic sources. Some of these sources contain critical information listeners need to comprehend; others are distractions that interfere with listeners6 comprehension. As the US population ages, a significant and growing segment have difficulty coping with such complex sound fi ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
A Clinical Decision Support Tool for Electronic Health Records
SBC: Inflexxion, Inc. Topic: NIDADESCRIPTION (provided by applicant): Substance abuse treatment is often complicated by problems such as depression, family and interpersonal conflicts, and legal issues. When these issues are addressed with effective, evidence-based treatments (EBTs), outcomes improve. To improve the quality of addiction treatment, experts have called for the adoption of a continuing care management approach, invo ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
ADAPTING PADLOCK-PROBE DETECTION SYSTEMS TO NCRNA DETECTION FOR CANCER DIAGNOSTICS
SBC: CUSTOMARRAY, INC. Topic: NCIThis proposal seeks to develop a cancer diagnostic based on microRNA (miRNA) expression patterns found in human serum. Mounting evidence is showing that patterns of miRNA expression and the appearance of these signals in circulating extra-cellular compartments are hallmarks of proliferating tumor cells. Our preliminary results have shown a clear ability to distinguish sera derived from cancer pati ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Adaptive Multi-Media Streaming for Android (AMMSTAR)
SBC: MZEAL COMMUNICATIONS, INC. Topic: SB102002Use of"Smartphones"and cellular networks is becoming an increasing priority for military applications. By placing the source of information directly with the solider on the ground via a Smartphone, the vision of"every soldier a sensor"becomes attainable. mZeal proposes to facilitate this vision with the Adaptive Multi-Media Streaming for Android (AMMSTAR) system. AMMSTAR will capture photographic ...
SBIR Phase I 2011 Department of DefenseDefense Advanced Research Projects Agency -
A device for rapid, painless, bedside muscle evaluation of children
SBC: MYOLEX, INC. Topic: NINDSDESCRIPTION (provided by applicant): Our goal is to provide neurologists and other clinicians a method for the rapid, painless, non-invasive evaluation of children with neuromuscular disease. Pediatric neuromuscular disorders include muscular dystrophies, spinal muscular atrophy, and inflammatory myositis, and affect well over 100,000 children in the United States alone. Present-day clinical m ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Advanced Gas Sensor
SBC: GINER INC Topic: NIOSHDESCRIPTION (provided by applicant): The underground use of diesel equipment introduces high concentrations of toxic gases such as CO, NO and NO2 into a confined atmosphere. The National Institute of Occupational Safety and Health (NIOSH) has determined that diesel exhaust is a potential human carcinogen, based on a combination of chemical, genotoxicity, and carcinogenicity data. This is due to th ...
SBIR Phase II 2011 Department of Health and Human ServicesCenters for Disease Control and Prevention -
Advanced Hypoglycemia Prevention Capabilities in Fuzzy Logic Artificial Pancreas
SBC: DOSE SAFETY INC Topic: NIDDKDESCRIPTION (provided by applicant): The ultimate technical objective of this research is the development of an Artificial Pancreas (AP) controller that improves metabolic control and decreases glycemic excursions by robustly preventing hypoglycemic episodes. Proportional-integral-derivative control (PID) and model predictive control (MPC) have been widely considered to be promising candidate for ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Advanced Laser Source for High-speed Adaptive Optics OCT
SBC: PHYSICAL SCIENCES INC. Topic: NEIDESCRIPTION (provided by applicant): Physical Sciences Inc. (PSI) proposes to develop a new adaptive optics imaging approach to high- speed 3D-retinal mapping with enhanced Fourier Domain Mode-locked (FDML) swept-source technology. PSI is currently engaged in ongoing development of high performance, high resolution multimodal adaptive optics (AO) retinal imagers. Such systems resolve and quant ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors
SBC: ARISAPH PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION (provided by applicant): Cancer is America's second leading cause of death. Many approved cancer drugs, such as bortezomib (Velcade), are cytotoxic agents that kill normal cells as well as tumor cells. Therapeutic benefit depends on tumor cellsbeing more sensitive than normal cells, thereby allowing clinical responses to be achieved at relatively safe drug doses; however, damage t ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health